Kathryn Romano

Recent appearances

• 

  Krystal Biotech, Inc. Q2 FY26 Earnings Call | Full Recording | KRYS

  August 03, 2026 · 📺 Alfa finder USA

  Full Krystal Biotech, Inc. (KRYS) Q2 FY26 earnings call — complete recording with CEO/CFO commentary and analyst Q&A. 📈 Growth: Reported revenue in Europe and Japan was flat for the quarter due to reserve provisions related to the ongoing pricing process in Germany. ⚠️ Risks: Management highlighted regulatory burdens in Japan and hospital-only administration requirements in France as potential barriers to treatment continuity and home access. 🎯 Outlook: The company plans to advance cystic fibrosis and Haley-Haley disease programs into registration development in 2027 and expects German pricin…

  Watch on YouTube ↗

• 

  $KRYS Krystal Q1 2024 Earnings Conference Call

  May 06, 2024 · 📺 EARNMOAR

  05/06/2024 Q&A: 33:37 Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is…

  Watch on YouTube ↗